Acción RYTM RHYTHM PHARMACEUTICALS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Rhythm Pharmaceuticals, Inc.

Acciones

RYTM

US76243J1051

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:00:00 25/06/2024 		Varia. Cinco días. Varia. 1 de enero.
42,75 USD +0,52 % Gráfico intradía de Rhythm Pharmaceuticals, Inc. +3,29 % -7,00 %
10/06 Transcript : Rhythm Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
14/05 Transcript : Rhythm Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 02:20 PM

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for IMCIVREE for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
Rhythm Pharmaceuticals' Imcivree Gains UK Recommendation for Treating Bardet-Biedl Syndrome
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhythm Pharmaceuticals' Q1 Net Loss Widens as Revenue Increases; Shares Fall Pre-Bell
Rhythm Pharmaceuticals : RYTM 1Q2024 vFinal
Earnings Flash (RYTM) RHYTHM PHARMACEUTICALS Reports Q1 Revenue $26M, vs. Street Est of $26.9M
Rhythm Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhythm Pharmaceuticals to Sell $150 Million in Series A Convertible Preferred Stock
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción RYTM
  4. Noticias Rhythm Pharmaceuticals, Inc.
  5. Otros idiomas